nvq
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-Q
QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED
MANAGEMENT INVESTMENT COMPANY
Investment Company Act file number 811-22021
The Gabelli Healthcare & Wellness Rx Trust
 
(Exact name of registrant as specified in charter)
One Corporate Center
Rye, New York 10580-1422
 
(Address of principal executive offices) (Zip code)
Agnes Mullady
Gabelli Funds, LLC
One Corporate Center
Rye, New York 10580-1422
 
(Name and address of agent for service)
Registrant’s telephone number, including area code: 1-800-422-3554
Date of fiscal year end: December 31
Date of reporting period: March 31, 2009
Form N-Q is to be used by management investment companies, other than small business investment companies registered on Form N-5 (§§ 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than 60 days after the close of the first and third fiscal quarters, pursuant to rule 30b1-5 under the Investment Company Act of 1940 (17 CFR 270.30b1-5). The Commission may use the information provided on Form N-Q in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-Q, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-Q unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. § 3507.
 
 

 


 

Item 1. Schedule of Investments.
The Schedule(s) of Investments is attached herewith.
(GABELLI LOGO)
The Gabelli Healthcare & WellnessRx Trust
First Quarter Report
March 31, 2009
To Our Shareholders,
     The Gabelli Healthcare & WellnessRx Trust’s (the “Fund”) net asset value (“NAV”) total return was (6.1)% for the first quarter of 2009, compared with declines of 11.0%, 8.0%, and 10.5% for the Standard & Poor’s (“S&P”) 500 Index, the S&P 500 Health Care Index, and the S&P 500 Consumer Staples Index, respectively. The total return of the Fund’s publicly traded shares was (8.0)% during the first quarter. On March 31, 2009, the Fund’s NAV per share was $5.83, while the price of the publicly traded shares closed at $4.61 on the New York Stock Exchange.
     Enclosed is the investment portfolio as of March 31, 2009.
Comparative Results
Average Annual Returns through March 31, 2009 (a)
                         
                    Since
                    Inception
    Quarter   1 Year   (06/28/07)
Gabelli Healthcare & WellnessRx Trust
                       
NAV Total Return (b)
    (6.12 )%     (22.56 )%     (15.78 )%
Investment Total Return (c)
    (7.98 )     (30.08 )     (26.19 )
S&P 500 Index
    (10.98 )     (38.06 )     (28.71 )(d)
S&P 500 Health Care Index
    (8.00 )     (19.74 )     (17.43 )
S&P 500 Consumer Staples Index
    (10.54 )     (22.64 )     (10.52 )
 
(a)   Returns represent past performance and do not guarantee future results. Investment returns and the principal value of an investment will fluctuate. When shares are sold, they may be worth more or less than their original cost. Current performance may be lower or higher than the performance data presented. Visit www.gabelli.com for performance information as of the most recent month end. Performance returns for periods of less than one year are not annualized. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The S&P 500 Index is an unmanaged indicator of stock market performance. The S&P 500 Health Care Index is an unmanaged indicator of health care equipment and services, pharmaceuticals, biotechnology and life sciences stock performance. The S&P 500 Consumer Staples Index is an unmanaged indicator of food and staples retailing, food, beverage and tobacco, and household and personal products. Dividends are considered reinvested. You cannot invest directly in an index.
 
(b)   Total returns and average annual returns reflect changes in the NAV per share and reinvestment of distributions at NAV on the ex-dividend date and are net of expenses. Since inception return is based on an initial NAV of $8.00.
 
(c)   Total returns and average annual returns reflect changes in closing market values on the New York Stock Exchange and reinvestment of distributions. Since inception return is based on an initial offering price of $8.00.
 
(d)   From June 30, 2007, the date closest to the Fund’s inception for which data is available.

We have separated the portfolio managers’ commentary from the financial statements and investment portfolio due to corporate governance regulations stipulated by the Sarbanes-Oxley Act of 2002. We have done this to ensure that the content of the portfolio managers’ commentary is unrestricted. The financial statements and investment portfolio are mailed separately from the commentary. Both the commentary and the financial statements, including the portfolio of investments, will be available on our website at www.gabelli.com.

 


 

THE GABELLI HEALTHCARE & WELLNESSRx TRUST
SCHEDULE OF INVESTMENTS
March 31, 2009 (Unaudited)
                 
            Market  
Shares         Value  
       
COMMON STOCKS — 87.7%
       
       
Beverages — 6.8%
       
  45,000    
Dr. Pepper Snapple Group Inc.†
  $ 760,950  
  12,000    
Hansen Natural Corp.†
    432,000  
  70,000    
ITO EN Ltd.
    852,149  
  6,000    
ITO EN Ltd., Preference
    52,068  
  12,000    
PepsiCo Inc.
    617,760  
  14,000    
The Coca-Cola Co.
    615,300  
  133,000    
Vitasoy International Holdings Ltd.
    56,971  
       
 
     
       
 
    3,387,198  
       
 
     
 
       
Biotechnology — 2.4%
       
  25,000    
3SBio Inc., ADR†
    169,250  
  200    
Arena Pharmaceuticals Inc.†
    602  
  35,000    
Array Biopharma Inc.†
    92,400  
  7,000    
Cephalon Inc.†
    476,700  
  10,000    
Crucell NV, ADR†
    197,100  
  5,000    
Gilead Sciences Inc.†
    231,600  
  452,000    
Neose Technologies Inc.
    45,200  
       
 
     
       
 
    1,212,852  
       
 
     
 
       
Chemicals — 0.7%
       
  12,000    
International Flavors & Fragrances Inc.
    365,520  
       
 
     
 
       
Computer Software and Services — 0.1%
       
  5,000    
eResearchTechnology Inc.†
    26,300  
       
 
     
 
       
Consumer Services and Supplies — 0.4%
       
  12,000    
Weight Watchers International Inc.
    222,600  
       
 
     
 
       
Food — 27.8%
       
  12,800    
Cadbury plc, ADR
    387,840  
  40,000    
Campbell Soup Co.
    1,094,400  
  105,000    
Dean Foods Co.†
    1,898,400  
  50,000    
Del Monte Foods Co.
    364,500  
  10,000    
Diamond Foods Inc.
    279,300  
  22,000    
Flowers Foods Inc.
    516,560  
  20,000    
General Mills Inc.
    997,600  
  22,000    
Groupe Danone
    1,071,545  
  15,000    
H.J. Heinz Co.
    495,900  
  40,000    
Hain Celestial Group Inc.†
    569,600  
  17,000    
Kellogg Co.
    622,710  
  16,000    
Kerry Group plc, Cl. A
    326,518  
  66,000    
Kikkoman Corp.
    548,083  
  59,000    
Lifeway Foods Inc.†
    472,000  
  100,000    
Meiji Seika Kaisha Ltd. (a)
    349,548  
  15,000    
Morinaga Milk Industry Co. Ltd.
    44,704  
  40,000    
Nestlé SA
    1,352,192  
  10,000    
Parmalat SpA
    20,607  
  6,000    
Rock Field Co. Ltd.
    72,496  
  84,400    
Smart Balance Inc.†
    509,776  
  15,000    
The J.M. Smucker Co.
    559,050  
  80,000    
Tingyi (Cayman Islands) Holding Corp.
    92,483  
  17,000    
Wimm-Bill-Dann Foods OJSC, ADR†
    540,770  
  40,000    
YAKULT HONSHA Co. Ltd.
    708,794  
       
 
     
       
 
    13,895,376  
       
 
     
 
       
Food and Staples Retailing — 7.1%
       
  6,000    
Costco Wholesale Corp.
    277,920  
  40,000    
CVS Caremark Corp.
    1,099,600  
  12,000    
SUPERVALU Inc.
    171,360  
  35,000    
The Great Atlantic & Pacific Tea Co. Inc.†
    185,850  
  1,000    
Village Super Market Inc., Cl. A
    31,170  
  10,000    
Wal-Mart Stores Inc.
    521,000  
  24,000    
Walgreen Co.
    623,040  
  37,000    
Whole Foods Market Inc.
    621,600  
       
 
     
       
 
    3,531,540  
       
 
     
 
       
Health Care Equipment and Supplies — 16.8%
       
  28,187    
AMDL Inc.†
    22,831  
  161,813    
AMDL Inc.† (a)(b)
    131,069  
  39,500    
AngioDynamics Inc.†
    443,980  
  3,000    
Becton, Dickinson and Co.
    201,720  
  30,000    
Boston Scientific Corp.†
    238,500  
  17,000    
Covidien Ltd.
    565,080  
  35,000    
Cutera Inc.†
    223,650  
  18,100    
ev3 Inc.†
    128,510  
  28,000    
Greatbatch Inc.†
    541,800  
  10,000    
Henry Schein Inc.†
    400,100  
  15,000    
Hologic Inc†
    196,350  
  27,000    
Inverness Medical Innovations Inc.†
    719,010  
  14,000    
Kinetic Concepts Inc.†
    295,680  
  15,000    
Medical Action Industries Inc.†
    124,350  
  261,900    
Medical Nutrition USA Inc.†
    429,516  
  9,000    
Medtronic Inc.
    265,230  
  34,000    
Micrus Endovascular Corp.†
    202,980  
  550,000    
Northstar Neuroscience Inc.†
    1,050,500  
  12,000    
Orthofix International NV†
    222,240  
  21,000    
St. Jude Medical Inc.†
    762,930  
  4,000    
Stryker Corp.
    136,160  
  7,500    
Thermo Fisher Scientific Inc.†
    267,525  
  78,000    
Vascular Solutions Inc.†
    477,360  
  9,000    
Zimmer Holdings Inc.†
    328,500  
       
 
     
       
 
    8,375,571  
       
 
     
 
       
Health Care Providers and Services — 12.8%
       
  14,000    
Aetna Inc.
    340,620  
  12,000    
Amedisys Inc.†
    329,880  
  9,000    
AmerisourceBergen Corp.
    293,940  
See accompanying notes to schedule of investments.

2


 

THE GABELLI HEALTHCARE & WELLNESSRx TRUST
SCHEDULE OF INVESTMENTS (Continued)
March 31, 2009 (Unaudited)
                 
            Market  
Shares         Value  
       
COMMON STOCKS (Continued)
       
       
Health Care Providers and Services (Continued)
       
  8,000    
Cardinal Health Inc.
  $ 251,840  
  3,000    
Chemed Corp.
    116,700  
  376,100    
Continucare Corp.†
    714,590  
  12,000    
Express Scripts Inc.†
    554,040  
  15,000    
Genoptix Inc.†
    409,200  
  14,000    
Healthways Inc.†
    122,780  
  12,000    
IMS Health Inc.
    149,640  
  10,000    
McKesson Corp.
    350,400  
  9,000    
Medco Health Solutions Inc.†
    372,060  
  301,400    
Metropolitan Health Networks Inc.†
    443,058  
  24,000    
Omnicare Inc.
    587,760  
  12,000    
Owens & Minor Inc.
    397,560  
  22,000    
PSS World Medical Inc.†
    315,700  
  31,200    
UnitedHealth Group Inc.
    653,016  
       
 
     
       
 
    6,402,784  
       
 
     
 
       
Pharmaceuticals — 12.4%
       
  11,000    
Abbott Laboratories
    524,700  
  30,000    
Inspire Pharmaceuticals Inc.†
    121,800  
  36,000    
Johnson & Johnson
    1,893,600  
  18,500    
Matrixx Initiatives Inc.†
    303,400  
  25,000    
Mead Johnson Nutrition Co., Cl. A†
    721,750  
  13,000    
Merck & Co. Inc.
    347,750  
  46,000    
Pain Therapeutics Inc.†
    193,200  
  3,000    
Schering-Plough Corp.
    70,650  
  12,000    
Teva Pharmaceutical Industries Ltd., ADR
    540,600  
  35,000    
Wyeth
    1,506,400  
       
 
     
       
 
    6,223,850  
       
 
     
 
       
Real Estate Investment Trusts — 0.4%
       
  6,000    
Alexandria Real Estate Equities Inc.
    218,400  
       
 
     
       
TOTAL COMMON STOCKS
    43,861,991  
       
 
     
 
       
WARRANTS — 0.1%
       
       
Health Care Equipment and Supplies — 0.1%
       
  80,907    
AMDL Inc., expire 03/05/11† (a)(b)
    26,247  
       
 
     
                 
Principal         Market  
Amount         Value  
       
U.S. GOVERNMENT OBLIGATIONS — 12.2%
       
       
U.S. Treasury Bills — 7.0%
       
$ 3,531,000    
U.S. Treasury Bills, 0.152% to 0.173%††, 06/04/09 to 07/02/09
  $ 3,529,459  
       
 
     
 
       
U.S. Treasury Cash Management Bills — 5.2%
       
  2,598,000    
U.S. Treasury Cash Management Bills, 0.051% to 0.122%††, 04/29/09 to 06/24/09
    2,597,183  
       
 
     
 
       
TOTAL U.S. GOVERNMENT OBLIGATIONS
    6,126,642  
       
 
     
       
 
       
TOTAL INVESTMENTS — 100.0%
     (Cost $65,995,601)
  $ 50,014,880  
       
 
     
       
Aggregate book cost
  $ 65,995,601  
       
 
     
       
Gross unrealized appreciation
  $ 600,230  
       
Gross unrealized depreciation
    (16,580,951 )
       
 
     
       
Net unrealized appreciation/(depreciation)
  $ (15,980,721 )
       
 
     
 
(a)   Security fair valued under procedures established by the Board of Trustees. The procedures may include reviewing available financial information about the company and reviewing the valuation of comparable securities and other factors on a regular basis. At March 31, 2009, the market value of fair valued securities amounted to $506,864 or 1.01% of total investments.
 
(b)   Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At March 31, 2009, the market value of Rule 144A securities amounted to $157,316 or 0.31% of total investments.
 
  Non-income producing security.
 
††   Represents annualized yield at date of purchase.
 
ADR American Depositary Receipt
                 
    % of        
    Market     Market  
Geographic Diversification   Value     Value  
North America
    83.7 %   $ 41,843,841  
Europe
    8.9       4,437,172  
Japan
    5.2       2,627,843  
Latin America
    2.1       1,049,053  
Asia/Pacific
    0.1       56,971  
 
           
Total Investments
    100.0 %   $ 50,014,880  
 
           
See accompanying notes to schedule of investments.

3


 

THE GABELLI HEALTHCARE & WELLNESSRx TRUST
NOTES TO SCHEDULE OF INVESTMENTS (Unaudited)
1. Security Valuation. Portfolio securities listed or traded on a nationally recognized securities exchange or traded in the U.S. over-the-counter market for which market quotations are readily available are valued at the last quoted sale price or a market’s official closing price as of the close of business on the day the securities are being valued. If there were no sales that day, the security is valued at the average of the closing bid and asked prices or, if there were no asked prices quoted on that day, then the security is valued at the closing bid price on that day. If no bid or asked prices are quoted on such day, the security is valued at the most recently available price or, if the Board of Trustees (the “Board”) so determines, by such other method as the Board shall determine in good faith to reflect its fair market value. Portfolio securities traded on more than one national securities exchange or market are valued according to the broadest and most representative market, as determined by Gabelli Funds, LLC, the Adviser.
Portfolio securities primarily traded on a foreign market are generally valued at the preceding closing values of such securities on the relevant market, but may be fair valued pursuant to procedures established by the Board if market conditions change significantly after the close of the foreign market but prior to the close of business on the day the securities are being valued. Debt instruments with remaining maturities of 60 days or less that are not credit impaired are valued at amortized cost, unless the Board determines such amount does not reflect the securities’ fair value, in which case these securities will be fair valued as determined by the Board. Debt instruments having a maturity greater than 60 days for which market quotations are readily available are valued at the average of the latest bid and asked prices. If there were no asked prices quoted on such day, the security is valued using the closing bid price. Futures contracts are valued at the closing settlement price of the exchange or board of trade on which the applicable contract is traded.
Securities and assets for which market quotations are not readily available are fair valued as determined by the Board.
Statement of Financial Accounting Standard No. 157, “Fair Value Measurements” (“SFAS 157”) clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value, and requires additional disclosures about the use of fair value measurements. The three levels of the fair value hierarchy under SFAS 157 are described below:
    Level 1 – quoted prices in active markets for identical securities;
 
    Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.); and
 
    Level 3 – significant unobservable inputs (including the Fund’s determinations as to the fair value of investments).
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of the Fund’s investments by inputs used to value the Fund’s investments as of March 31, 2009 is as follows:
         
    Investments in  
    Securities  
    (Market Value)  
Valuation Inputs   Assets  
Level 1 – Quoted Prices
  $ 43,512,444  
Level 2 – Other Significant Observable Inputs
    6,152,888  
Level 3 – Significant Unobservable Inputs
    349,548  
 
     
Total
  $ 50,014,880  
 
     

4


 

THE GABELLI HEALTHCARE & WELLNESSRx TRUST
NOTES TO SCHEDULE OF INVESTMENTS (Continued) (Unaudited)
The following is a reconciliation of Level 3 investments for which significant unobservable inputs were used to determine fair value:
         
    Investments in  
    Securities  
    (Market Value)  
Balance as of 12/31/08
     
Accrued discounts/(premiums)
     
Realized gain/(loss)
     
Change in unrealized appreciation/(depreciation)
     
Net purchase/(sales)
     
Transfers in and/or out of Level 3
  $ 349,548  
 
     
 
Balance as of 03/31/09
  $ 349,548  
 
     
 
       
Net change in unrealized appreciation/(depreciation) during the period on Level 3 investments held at 03/31/09
  $ 142,237  
 
     
Statement of Financial Accounting Standard No. 161, “Disclosures about Derivative Instruments and Hedging Activities” clarifies the financial reporting for derivative instruments by requiring enhanced disclosure that enables investors to understand how and why an entity uses derivatives, how derivatives are accounted for, and how derivative instruments affect an entity’s results of operations and financial position. As of March 31, 2009, the Fund did not hold any derivative instruments.
2. Tax Information. At December 31, 2008, the Fund had net capital loss carryforwards for federal income tax purposes of $1,540,875 which are available to reduce future required distributions of net capital gains to shareholders through 2016.

5


 

THE GABELLI HEALTHCARE & WELLNESSRx TRUST
AND YOUR PERSONAL PRIVACY
Who are we?
The Gabelli Healthcare & WellnessRx Trust (the “Fund”) is a closed-end management investment company registered with the Securities and Exchange Commission under the Investment Company Act of 1940. We are managed by Gabelli Funds, LLC, which is affiliated with GAMCO Investors, Inc. GAMCO Investors, Inc. is a publicly held company that has subsidiaries that provide investment advisory or brokerage services for a variety of clients.
What kind of non-public information do we collect about you if you become a shareholder?
When you purchase shares of the Fund on the New York Stock Exchange, you have the option of registering directly with our transfer agent in order, for example, to participate in our dividend reinvestment plan.
  Information you give us on your application form. This could include your name, address, telephone number, social security number, bank account number, and other information.
 
  Information about your transactions with us. This would include information about the shares that you buy or sell; it may also include information about whether you sell or exercise rights that we have issued from time to time. If we hire someone else to provide services—like a transfer agent—we will also have information about the transactions that you conduct through them.
What information do we disclose and to whom do we disclose it?
We do not disclose any non-public personal information about our customers or former customers to anyone other than our affiliates, our service providers who need to know such information, and as otherwise permitted by law. If you want to find out what the law permits, you can read the privacy rules adopted by the Securities and Exchange Commission. They are in volume 17 of the Code of Federal Regulations, Part 248. The Commission often posts information about its regulations on its website, www.sec.gov.
What do we do to protect your personal information?
We restrict access to non-public personal information about you to the people who need to know that information in order to provide services to you or the Fund and to ensure that we are complying with the laws governing the securities business. We maintain physical, electronic, and procedural safeguards to keep your personal information confidential.

 


 

TRUSTEES AND OFFICERS
THE GABELLI HEALTHCARE & WELLNESS
Rx TRUST
One Corporate Center, Rye, NY 10580-1422

         
Trustees        
Mario J. Gabelli, CFA
Chairman & Chief Executive Officer,
GAMCO Investors, Inc.
 
Dr. Thomas E. Bratter
President & Founder, John Dewey Academy
 
Anthony J. Colavita
Attorney-at-Law,
Anthony J. Colavita, P.C.
 
James P. Conn
Former Managing Director &
Chief Investment Officer,
Financial Security Assurance Holdings Ltd.
 
Vincent D. Enright
Former Senior Vice President &
Chief Financial Officer,
KeySpan Corp.
 
Robert C. Kolodny, MD
Physician, Author, and Lecturer,
General Partner of KBS Partnership
 
Anthonie C. van Ekris
Chairman, BALMAC International, Inc.
 
Salvatore J. Zizza
Chairman, Zizza & Co., Ltd.
     
Officers    
Bruce N. Alpert
Secretary
   
 
   
Carter W. Austin
   
Vice President
   
 
   
Peter D. Goldstein
   
Chief Compliance Officer
   
 
   
Agnes Mullady
   
President & Treasurer
   
 
   
David I. Schachter
   
Vice President
   
 
   
Adam E. Tokar
   
Assistant Vice President & Ombudsman
   
 
   
Investment Adviser
   
Gabelli Funds, LLC
   
One Corporate Center
   
Rye, New York 10580-1422
   
 
   
Custodian
   
The Bank of New York Mellon
   
 
   
Counsel
   
Willkie Farr & Gallagher LLP
   
 
   
Transfer Agent and Registrar
   
Computershare Trust Company, N.A.
   
 
   
Stock Exchange Listing
   
 
  Common
 
 
NYSE–Symbol:
  GRX
Shares Outstanding:
  8,474,459


The Net Asset Value per share appears in the Publicly Traded Funds column, under the heading “Specialized Equity Funds,” in Monday’s The Wall Street Journal. It is also listed in Barron’s Mutual Funds/Closed End Funds section under the heading “Specialized Equity Funds.”
The Net Asset Value per share may be obtained each day by calling (914) 921-5070 or visiting www.gabelli.com.

For general information about the Gabelli Funds, call 800-GABELLI (800-422-3554), fax us at 914-921-5118, visit Gabelli Funds’ Internet homepage at: www.gabelli.com, or e-mail us at: closedend@gabelli.com

Notice is hereby given in accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may, from time to time, purchase its common shares in the open market when the Fund’s shares are trading at a discount of 10% or more from the net asset value of the shares.

 


 

(IMAGE)
THE GABELLI HEALTHCARE & WELLNESS RxTRUST One Corporate Center Rye, NY 10580-1422 (914) 921-5070 www.gabelli.com First Quarter Report March 31, 2009

 


 

Item 2. Controls and Procedures.
  (a)   The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”) (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)).
 
  (b)   There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d)) that occurred during the registrant’s last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.
Item 3. Exhibits.
Certifications pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto.

 


 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
           
(Registrant) The Gabelli Healthcare & Wellness Rx Trust      
 
By (Signature and Title)*  /s/ Agnes Mullady    
  Agnes Mullady, Principal Executive Officer and    
  Principal Financial Officer   
Date 5/29/09
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
           
By (Signature and Title)*  /s/ Agnes Mullady    
  Agnes Mullady, Principal Executive Officer and    
  Principal Financial Officer   
Date 5/29/09
 
*   Print the name and title of each signing officer under his or her signature.